Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 682,644 | 817,609 | 801,713 | 866,562 | -363,295 |
| Depreciation Amortization | 22,012 | 13,847 | 8,635 | 5,207 | 223,880 |
| Income taxes - deferred | -3 | -4 | N/A | 2 | -55,912 |
| Accounts receivable | -10,151 | -32,365 | -25,891 | -47,792 | 1,732 |
| Other Working Capital | -52,564 | -143,677 | -58,801 | -42,081 | 100,743 |
| Other Operating Activity | 69,258 | 90,059 | 86,114 | 88,205 | -14,836 |
| Operating Cash Flow | $711,196 | $745,469 | $811,770 | $870,103 | $-107,688 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -508,414 | -633,341 | -599,913 | -181,898 | -248 |
| PPE Investments | -8,790 | -6,416 | -2,971 | -1,654 | 21,554 |
| Net Acquisitions | -291,152 | N/A | -3,485 | N/A | -67,747 |
| Purchase Of Investment | -53,628 | N/A | N/A | N/A | -59,377 |
| Purchase Sale Intangibles | N/A | -256,235 | N/A | -808 | N/A |
| Other Investing Activity | 0 | -256,235 | 0 | -808 | 150,000 |
| Investing Cash Flow | $-861,984 | $-895,992 | $-606,369 | $-184,360 | $44,182 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -1,611 | -7,952 | N/A | N/A | -1,490 |
| Common Stock Issued | 99,046 | 36,542 | 19,712 | 15,751 | 33,764 |
| Other Financing Activity | 233,659 | 0 | -6,341 | -6,341 | 223,592 |
| Financing Cash Flow | $331,094 | $28,590 | $13,371 | $9,410 | $255,866 |
| Exchange Rate Effect | 22,712 | 12,917 | 18,981 | 5,393 | -7,328 |
| Beginning Cash Position | 795,316 | 795,316 | 795,316 | 795,316 | 610,284 |
| End Cash Position | 998,334 | 686,300 | 1,033,069 | 1,495,862 | 795,316 |
| Net Cash Flow | $203,018 | $-109,016 | $237,753 | $700,546 | $185,032 |
| Free Cash Flow | |||||
| Operating Cash Flow | 711,196 | 745,469 | 811,770 | 870,103 | -107,688 |
| Capital Expenditure | -8,860 | -6,486 | -3,041 | -1,724 | -6,502 |
| Free Cash Flow | 702,336 | 738,983 | 808,729 | 868,379 | -114,190 |